Efficacy and Safety of Long-Term Anticoagulation Therapy with Direct Oral Anticoagulants versus Vitamin K Antagonist in Patients with Cerebral Venous Thrombosis
Table 2.
Characteristics of reviewed studies
|
| Study (Year) |
Anticoagulant |
Time to initiation of AC (days) |
Duration of AC |
Recanalization |
No Recanalization |
Any Bleeding |
New Intracranial Hemorrhage |
Functional Outcome |
Mortality |
|
|
| Ferro et al (2019) |
Warfarin
Dabigatran |
5-15 |
5.15 |
35 (67%)
33 (60%) |
17 (33%)
22 (40%) |
12 (20%)
12 (20%) |
2(3.8%)
0 (0%) |
mRS 0-2: 56 (96.6%)mRS 3-5: 2 (2.3%)
mRS 0-2 :58 (98.3%)mRS 3-5: 1 (1.7%) |
0 (0%)
0 (0%) |
|
| Connor et al (2020) |
Heparin/VKA
Rivaroxaban
|
5-9 |
3 |
30 (73%)
57 (78%) |
11 (27%)
16 (22%) |
1 (2.4%)
5 (6.8%) |
1 (2.4%)
0 (0%) |
Recurrent CVT/Hemorrhage: 2 (4.9%)
Recurrent CVT/Hemorrhage: 0 (0%) |
0 (0%)
0 (0%) |
|
| Khorvash et al (2021) |
Warfarin
Rivaroxaban |
2 |
3 |
NR |
NR |
0 (0%)
1 (4%) |
On Admission: 7 (28%)
Month 3: 0 (0%)
Month 6:0 (0%)
On Admission::2 (8%)
Month 3:1 (4%)
Month 6:(0%) |
mRS
On Admission: 3 (2.0, 4.0)1
Month 3: 1 (0, 2.0)1
Month 6: 0 (0, 2.0)1
mRS
On Admission:: 3 (1.5, 4.0)1
Month 3: 1 (0, 1.0)1
Month 6: 0 (0, 1.0)1 |
0 (0%)
0 (0%) |
|
| Masqood et al (2021) |
Warfarin
Rivaroxaban |
5 |
3-12 |
Month 3
17 (71%)
Month 6
20 (83%)
Bulan ke-12
24 (100%)
Month 3
15 (71%)
Month 6
18 (86%)
Month 12
21 (100%) |
Month 3
7 (29%)
Month 6
4 (17%)
Month 12
0 (0%)
Month 3
6 (29%)
Month 6
3 (14%)
Month 12
0 (0%) |
6 (25%)
2 (10%) |
2 (8%)
0 (0%) |
NIHSS2
Month 3
NIHSS 0: 21 (88%)
NIHSS 1-4: 3 (12%)
Month 6
NIHSS 0: 23 (96%)
NIHSS 1-4: 1 (4%)
Month 3
NIHSS 0: 20 (95%)
NIHSS 1-4: 1 (5%)
Month 6
NIHSS 0: 20 (95%)
NIHSS 1-4: 1 (5%) |
0 (0%)
0 (0%) |
|
|
1 Data is shown as Median (first quartile, third quartile)
2 Data is reported as NIHSS (National Institutes of Health Stroke Scale)
Abbreviations: AC, Anticoagulation; CVT: Cerebral Venous Thrombosis; LMWH: Low Molecular Weight Hepa-rin; UFH, Unfractionated Heparin; mRS, Modified Rankin Scale; NR: Not Reported; VKA, Vitamin K Antagonist
|
|
